Approaching Complex Pain in a Child with a Vaso-Occlusive Crisis: A Clinical Case
DOI:
https://doi.org/10.25751/rspa.25723Keywords:
Neuropatic Pain, Drepanocytosis, Pediatric, GabapentinAbstract
Pain from the vaso-occlusive crisis of sickle cell disease is a frequent and debilitating manifestation. While the nociceptive component is easily recognized and potentially controlled with conventional therapy, the neuropathic component is underdiagnosed and undertreated. There is little evidence for the use of membrane stabilizers, indicated in neuropathic pain (NP), in sickle cell disease. We present the case of a 7-year-old child with multiple hospitalizations and uncontrolled pain under conventional therapy and opioids. Gabapentin was shown to be effective in pain control and the present work contributes to the evidence that NP is a reality in these patients.
Downloads
References
Sharma, D. & Brandow, A. M. Neuropathic pain in individuals with sickle cell disease. Neu-rosci. Lett. 714, 134445 (2019).
Toste, S., Palhau, I. L. & Amorim, I. R. Dor Neuropática em Idade Pediátrica Neuropathic. Rev. da Soc. Port. Med. Física e Reabil. 27, 22–29 (2015).
Brandow, A. M., Farley, R. A., Desgupta, M., Hoffmann, R. G. & Panepinto, J. A. The Use of Neuropathic Pain Drugs in Children with Sickle Cell Disease is Associated with Older Age, Female Gender and Longer Length of Hospital stay. J Pediatr Hematol Oncol 37, 10–15 (2015).
Nottage, K. A. et al. Addressing challenges of clinical trials in acute pain: The Pain Manage-ment of Vaso-occlusive Crisis in Children and Young Adults with Sickle Cell Disease Study. Clin. Trials 13, 409–416 (2016).
Ballas SK, Darbari DS. Neuropathy, neuropathic pain, and sickle cell disease. Am J Hematol 88(11), 927‐9 (2013).
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Larissa Morais, Inês Portela, Ana Paulino, Célia Xavier

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Articles are freely available to be read, downloaded and shared from the time of publication.
The RSPA reserves the right to commercialize the article as an integral part of the journal (in the preparation of reprints, for example). The author should accompany the submission letter with a declaration of copyright transfer for commercial purposes.
Articles are published under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC).
After publication in RSPA, authors are allowed to make their articles available in repositories of their home institutions, as long as they always mention where they were published.